Format

Send to

Choose Destination
Infect Immun. 2019 Sep 19;87(10). pii: e00506-19. doi: 10.1128/IAI.00506-19. Print 2019 Oct.

Bordetella Colonization Factor A (BcfA) Elicits Protective Immunity against Bordetella bronchiseptica in the Absence of an Additional Adjuvant.

Author information

1
Department of Microbial Infection and Immunity, The Ohio State University, Columbus, Ohio, USA.
2
Department of Microbiology and Immunology, Wake Forest University Health Sciences, Winston-Salem, North Carolina, USA.
3
College of Veterinary Medicine, Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA.
4
Human Immunology Center Laboratory, University of Rochester Medical Center, Rochester, New York, USA.
5
Department of Microbial Infection and Immunity, The Ohio State University, Columbus, Ohio, USA rajendar.deora@osumc.edu purnima.dubey@osumc.edu.
6
Department of Microbiology, The Ohio State University, Columbus, Ohio, USA.

Abstract

Bordetella bronchiseptica is an etiologic agent of respiratory diseases in animals and humans. Despite the widespread use of veterinary B. bronchiseptica vaccines, there is limited information on their composition and relative efficacy and on the immune responses that they elicit. Furthermore, human B. bronchiseptica vaccines are not available. We leveraged the dual antigenic and adjuvant functions of Bordetella colonization factor A (BcfA) to develop acellular B. bronchiseptica vaccines in the absence of an additional adjuvant. BALB/c mice immunized with BcfA alone or a trivalent vaccine containing BcfA and the Bordetella antigens FHA and Prn were equally protected against challenge with a prototype B. bronchiseptica strain. The trivalent vaccine protected mice significantly better than the canine vaccine Bronchicine and provided protection against a B. bronchiseptica strain isolated from a dog with kennel cough. Th1/17-polarized immune responses correlate with long-lasting protection against bordetellae and other respiratory pathogens. Notably, BcfA strongly attenuated the Th2 responses elicited by FHA and Prn, resulting in Th1/17-skewed responses in inherently Th2-skewed BALB/c mice. Thus, BcfA functions as both an antigen and an adjuvant, providing protection as a single-component vaccine. BcfA-adjuvanted vaccines may improve the efficacy and durability of vaccines against bordetellae and other pathogens.

KEYWORDS:

BcfA; Bordetella ; adjuvant; antigen; vaccines

PMID:
31308083
PMCID:
PMC6759310
[Available on 2020-03-19]
DOI:
10.1128/IAI.00506-19
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center